Competing drug pricing visions aired

On Tuesday, a group of six biotech CEOs and a generic drug industry advocate outlined competing visions to address controversies over the price of prescription drugs.

In a commentary posted on Forbes, the CEO group drew a sharp distinction between the innovative and generic drug industries. They called for "fixes to

Read the full 513 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE